Postmenopausal osteoporosis: a gynecologist’s view
DOI: 10.32364/2587-6821-2020-4-6-358-363
I.Yu. Il’ina, Yu.E. Dobrokhotova
Pirogov Russian National Research Medical University, Moscow, Russian Federation
Climacteric is a physiological period of woman’s life starting from the decline in ovarian activity until the end of ovarian function. The end of ovarian function associated with the significant reduction in estradiol progestin synthesis results in the hormonal changes that lead to the clinical manifestations of postmenopausal period. During this period, metabolic disorders and cardiovascular events are common. In addition, the risks of various cancers (i.e., breast, colorectal, pancreatic, bladder, and endometrial cancer) increase greatly. Moreover, the risk of osteoporosis, a condition that affects the quality of life, also increases. Considering this, menopausal hormone therapy and drugs promoting bone metabolism should be prescribed in addition to the changes in the lifestyle and encouraging physical activity.
Keywords: menopause, climax, bone mineral density, fractures, osteoporosis, ibandronic acid.
For citation: Il’ina I.Yu., Dobrokhotova Yu.E. Postmenopausal osteoporosis: a gynecologist’s view. Russian Medical Inquiry. 2020;4(6):358–363. DOI: 10.32364/2587-6821-2020-4-6-358-363.
Acknowledgement
Editorial Board is grateful to LLC "Pharm-Sintez" for the assistance in technical edition of this publication.
About the authors:
Irina Yu. Il’ina — Doct. of Sci. (Med.)., Professor of the Department of Obstetrics and Gynecology of the Medical Faculty, Pirogov Russian National Research Medical University, 1, Ostrovityanov str., Moscow, 117437, Russian Federation; ORCID iD 0000-0001-8155-8775.
Yuliya E. Dobrokhotova — Doct. of Sci. (Med.)., Professor of the Department of Obstetrics & Gynecology of the Medical Faculty, Pirogov Russian National Research Medical University, 1, Ostrovityanov str., Moscow, 117437, Russian Federation; ORCID iD 0000-0002-7830-2290.
Contact information: Irina Yu. Il’ina, e-mail: iliyina@mail.ru. Financial Disclosure: no authors have a financial or property interest in any material or method mentioned. There is no conflict of interests. Received 08.09.2020, revised 22.09.2020, accepted 04.10.2020.
2. Smetnik V.P. Menopause medicine. M.: Litera; 2006 (in Russ.).
3. Dobrokhotova Yu.E., Ilyina I.Yu. Posthysterectomy syndrome. Diagnostics and treatment. M.: GEOTAR-Media; 2017 (in Russ.).
4. Osteoporosis. Clinical guidelines. М.; 2019 (in Russ.).
5. Menopause. Translation fr om English. ed. V.P. Smetnik. M.: GEOTAR-Media; 2011 (in Russ.).
6. Khan A., Fortier M. Osteoporosis in menopause. Menopause and Osteoporosis Working Group. J Obstet Gynaecol Can. 2014;36(9):839–840. DOI: 10.1016/S1701-2163 (15) 30489-8.
7. Eastell R., Szulc P. Use of bone turnover markers in postmenopausal osteoporosis. Lancet Diabetes Endocrinol. 2017;5(11):908–923. DOI: 10.1016/S2213-8587 (17) 30184-5.
8. Miller P.D. Management of severe osteoporosis. Expert Opin Pharmacother. 2016;17(4):473–488. DOI: 10.1517/14656566.2016.1124856.
9. Kettail V.M., Arches R.A. Pathophysiology of the endocrine system. М.: Binom; 2019 (in Russ.).
10. Povoroznyuk V.V., Reznichenko N.A., Maylyan E.A. Immunological aspects of postmenopausal osteoporosis. Bol’. Sustavy. Pozvonochnik. 2013;3(11):21–26 (in Russ.).
11. Muhammad A., Mada S.B., Malami I. et al. Postmenopausal osteoporosis and breast cancer: The biochemical links and beneficial effects of functional foods. Biomed Pharmacother. 2018;107:571–582. DOI: 10.1016/j.biopha.2018.08.018.
12. Hallajzadeh J., Khoramdad M., Izadi N. et al. Metabolic syndrome and its components in premenopausal and postmenopausal women: a comprehensive systematic review and meta-analysis on observational studies. Menopause. 2018;25(10):1155–1164. DOI: 10.1097/GME.0000000000001136.
13. Ikeda K., Horie-Inoue K., Inoue S. Functions of estrogen and estrogen receptor signaling on skeletal muscle. J Steroid Biochem Mol Biol. 2019;191:105375. DOI: 10.1016/j.jsbmb.2019.105375.
14. El Maghraoui A., Rezqi A., El Mrahi S. et al. Osteoporosis, vertebral fractures and metabolic syndrome in postmenopausal women. BMC Endocr Disord. 2014;14:93. DOI: 10.1186/1472-6823-14-93.
15. Abbasi M., Farzam S.A., Mamaghani Z., Yazdi Z. Relationship between metabolic syndrome and its components with bone densitometry in postmenopausal women. Diabetes Metab Syndr. 2017;11(Suppl 1):S73–S76. DOI: 10.1016/j.dsx.2016.12.008.
16. Stojanovic S.S., Arsenijevic N.A., Djukic A. et al. Adiponectin as a potential biomarker of low bone mineral density in postmenopausal women with metabolic syndrome. Acta Endocrinol (Buchar). 2018;14(2):201–207. DOI: 10.4183/aeb.2018.201.
17. Yureneva S.V., Ilyina L.M. A practical guide for physicians on the management of women in transition and postmenopausal women. М.; 2017 (in Russ.).
18. Protasova A.E., Yureneva S.V., Bayramova N.N., Komedina V.I. Menopause, obesity and comorbidity: the possibilities of menopausal hormone therapy. Akusherstvo i ginekologiya. 2019;5:43–48 (in Russ.). DOI: 10.18565/aig.2019.5.43-48.
19. Schmitt E.B., Nahas-Neto J., Bueloni-Dias F. et al. Vitamin D deficiency is associated with metabolic syndrome in postmenopausal women. Maturitas. 2018;107:97–102. DOI: 10.1016/j.maturitas.2017.10.011.
20. Dobrokhotova Yu.E., Dugieva M.Z. Postmanopsaus osteoporosis: calcium preparations in the modern prevention and treatment strategy. RMJ. 2017;15:1135-1139 (in Russ.).
21. Savchenko T.N., Agaeva M.I., Nosova L.A., Shapovalova Yu.O. Prevention of osteoporosis in women. RMJ. 2017;12:879-883 (in Russ.).
22. Grigoryan O.R., Pokusaeva V.N., Andreeva E.N. et al. Obesity and menopause. Obesity in women. Ed. G.A. Melnichenko, N.K. Nikiforovsky. M.: Medical Information Agency; 2017 (in Russ.).
23. Zaydieva Ya.Z. Alternative therapy of menopausal disorders in women of climacterical age (literature review). RMJ. 2017;12:873-878 (in Russ.).
24. Narimanova M.R., Saprykina L.V. The efficacy of non-hormone therapy for atrophic vaginitis in postmenopausal women. Russian Journal of Woman and Child Health. 2019;2(3):257–261 (in Russ.). DOI: 10.32364/2618-8430-2019-2-3-257-261.
25. Andreeva E.N., Sheremetyeva E.V. Mental aspects and violation of fat metabolism in menopause Akusherstvo i ginekologiya. 2019;9:165–172 (in Russ.). DOI: 10.18565/aig.2019.9.165-172.
26. Collins Fantasia H., Sutherland M.A. Hormone therapy for the management of menopause symptoms. J Obstet Gynecol Neonatal Nurs. 2014;43(2):226–235. DOI: 10.1111/1552-6909.12282.
27. Dobrokhotova Yu.E., Il’ina I.Yu., Narimanova M.R., Ibragimova J.M. Metabolic syndrome in postmenopausal women. Russian journal of Woman and Child Health. 2018;1(1):33–38 (in Russ.). DOI: 10.32364/2618-8430-2018-1-1-33-38.
28. Sandakova E.A., Zhukovskaya I.G. Menopausal transition and early postmenopause in women with obesity of various types and degrees. Russian Journal of Woman and Child Health (in Russ.). 2019;2(1):16–22. DOI: 10.32364/2618-8430-2019-2-1-16-22.
29. Recommendations for the management of patients with metabolic syndrome. Clinical guidelines. М.; 2013 (in Russ.).
30. Huang A.J., Sawaya G.F., Vittinghoff E. et al. Hot flushes, coronary heart disease, and hormone therapy in postmenopausal women. Menopause. 2018;25(11):1286–1290. DOI: 10.1097/GME.0000000000001230.
31. Lobo R.A. Hormone-replacement therapy: current thinking. Nat Rev Endocrinol. 2017;13(4):220–231. DOI: 10.1038/nrendo.2016.164.
32. Main C., Knight B., Moxham T. et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev. 2013;30(4):CD002229.
33. Roberts H., Hicke M. Managing the menopause: An update. Maturitas. 2016;86:53–58. DOI: 10.1038/nrendo.2016.164.
34. Anagnostis P., Paschou S.A., Katsiki N. et al. Menopausal Hormone Therapy and Cardiovascular Risk: Wh ere are we Now? Curr Vasc Pharmacol. 2019;17(6):564–572. DOI: 10.2174/1570161116666180709095348.
35. Yureneva S.V. Optimization of MHT risks: monotherapy with transdermal estrogens or in combination with micronized progesterone. Benefits against venous thromboembolism and breast cancer. Akusherstvo i ginekologiya. 2015;5:19–25 (in Russ.).
36. Liu G.F., Wang Z.Q., Liu L. et al. A network meta-analysis on the short-term efficacy and adverse events of different anti-osteoporosis drugs for the treatment of postmenopausal osteoporosis. J Cell Biochem. 2018;119(6):4469–4481. DOI: 10.1002/jcb.26550.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Распечатать